Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metastatic malignant melanoma.

J B Meric1, O Rixe, D Khayat

  • 1SOMPS, Salpetriere Hospital, Paris, France.

Drugs of Today (Barcelona, Spain : 1998)
|February 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.

Breast cancer research and treatment·2013
Same author

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer.

Cancer chemotherapy and pharmacology·2012
Same author

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

British journal of cancer·2012
Same author

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Medical oncology (Northwood, London, England)·2011
Same author

Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Malignant melanoma is an aggressive cancer with poor survival rates. While chemotherapy offers limited benefits, chemoimmunotherapy, combining cytokines like interleukin-2 (IL-2) with chemotherapy, shows promise but requires further study due to toxicity.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Epidemiology

Background:

  • Malignant melanoma incidence is rising, posing a significant public health concern.
  • Advanced melanoma is aggressive, chemoresistant, and associated with poor prognosis (90-95% mortality within 3 years).
  • Conventional chemotherapy demonstrates limited efficacy in improving melanoma patient survival.

Purpose of the Study:

  • To review the efficacy and challenges of various treatment strategies for malignant melanoma.
  • To evaluate the role of cytokines, specifically interferon-alpha and interleukin-2 (IL-2), in melanoma treatment.
  • To assess the potential of chemoimmunotherapy, including cisplatin and IL-2 combinations, in improving patient outcomes.

Main Methods:

  • Review of existing literature on melanoma treatment modalities.

Related Experiment Videos

  • Analysis of studies investigating cytokine therapy (interferon-alpha, IL-2) in malignant melanoma.
  • Examination of chemoimmunotherapy strategies, including drug combinations and dosing schedules.

    • Main Results:

    • Cytokine therapy (interferon-alpha, IL-2) shows higher response and survival rates than chemotherapy alone.
    • Chemoimmunotherapy, particularly cisplatin and IL-2 combinations, is explored for enhanced efficacy.
    • Long-term unmaintained remissions are observed with cytokine-based treatments.

    Conclusions:

    • Malignant melanoma remains a challenging malignancy with limited effective treatments.
    • Chemoimmunotherapy presents a potential therapeutic avenue, but its overall survival benefit requires further validation due to associated toxicities.
    • Continued research into optimizing chemoimmunotherapy regimens is crucial for improving outcomes in advanced melanoma.